AR061668A1 - Jarabes antihistaminicos, estables al almacenamiento, sin azucar - Google Patents
Jarabes antihistaminicos, estables al almacenamiento, sin azucarInfo
- Publication number
- AR061668A1 AR061668A1 ARP070102860A ARP070102860A AR061668A1 AR 061668 A1 AR061668 A1 AR 061668A1 AR P070102860 A ARP070102860 A AR P070102860A AR P070102860 A ARP070102860 A AR P070102860A AR 061668 A1 AR061668 A1 AR 061668A1
- Authority
- AR
- Argentina
- Prior art keywords
- formulation
- stable
- storage
- antihistamine syrup
- antihistamine
- Prior art date
Links
- 230000001387 anti-histamine Effects 0.000 title abstract 5
- 239000000739 antihistaminic agent Substances 0.000 title abstract 5
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 abstract 4
- 238000009472 formulation Methods 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 4
- 239000006188 syrup Substances 0.000 abstract 4
- 235000020357 syrup Nutrition 0.000 abstract 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 abstract 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 abstract 1
- JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 abstract 1
- 239000004376 Sucralose Substances 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 230000000172 allergic effect Effects 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 abstract 1
- 229960001271 desloratadine Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000004968 inflammatory condition Effects 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 229960003088 loratadine Drugs 0.000 abstract 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
- 229940069328 povidone Drugs 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 229960004063 propylene glycol Drugs 0.000 abstract 1
- 210000002345 respiratory system Anatomy 0.000 abstract 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 abstract 1
- 235000010234 sodium benzoate Nutrition 0.000 abstract 1
- 239000004299 sodium benzoate Substances 0.000 abstract 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 abstract 1
- 229960000999 sodium citrate dihydrate Drugs 0.000 abstract 1
- 239000000600 sorbitol Substances 0.000 abstract 1
- 229960002920 sorbitol Drugs 0.000 abstract 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 abstract 1
- 235000019408 sucralose Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Otolaryngology (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicacion 1: Una formulacion de jarabe antihistamínico cuyos ingredientes comprenden loratadina, desloratadina o una sal farmacéuticamente aceptable de ellas o una combinacion de dos o más de las mismas, propilenglicol, sorbitol, citrato de sodio dihidrato, ácido cítrico anhidro, povidona, sucralosa, opcionalmente benzoato de sodio y opcionalmente ácido aminopolicarboxílico o una sal de éste, en la cual la formulacion de jarabe antihistamínico tiene un pH de más de 4,5; siendo dicha formulacion de jarabe antihistamínico estable al almacenamiento. Reivindicacion 19: El uso de la formulacion de jarabe antihistamínico de la afirmacion 1 u 11 para la fabricacion de un medicamento para el tratamiento y/o la prevencion de afecciones alérgicas e inflamatorias de la piel o las vías respiratorias en seres humanos que lo necesitan.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81731206P | 2006-06-29 | 2006-06-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR061668A1 true AR061668A1 (es) | 2008-09-10 |
Family
ID=38739452
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070102860A AR061668A1 (es) | 2006-06-29 | 2007-06-27 | Jarabes antihistaminicos, estables al almacenamiento, sin azucar |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20080262017A1 (es) |
| EP (1) | EP2037921A2 (es) |
| JP (1) | JP2009542665A (es) |
| KR (1) | KR20090024282A (es) |
| CN (1) | CN101505750A (es) |
| AR (1) | AR061668A1 (es) |
| AU (1) | AU2007269835A1 (es) |
| BR (1) | BRPI0713933A2 (es) |
| CA (1) | CA2656087A1 (es) |
| CL (1) | CL2007001913A1 (es) |
| CO (1) | CO6230988A2 (es) |
| MX (1) | MX2009000121A (es) |
| NO (1) | NO20090458L (es) |
| PE (1) | PE20080994A1 (es) |
| SG (1) | SG173333A1 (es) |
| TW (1) | TW200808374A (es) |
| WO (1) | WO2008005267A2 (es) |
| ZA (1) | ZA200900168B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101548959B (zh) * | 2008-04-03 | 2012-11-21 | 万特制药(海南)有限公司 | 一种含有地氯雷他定的包衣片剂及其制备方法 |
| WO2011146030A2 (en) * | 2010-05-18 | 2011-11-24 | Mahmut Bilgic | Effervescent antihistamine formulations |
| KR20190085561A (ko) | 2010-10-21 | 2019-07-18 | 알티유 파머수티컬즈, 엘엘시 | 즉시 사용가능한 케토로락 제제 |
| WO2013062497A1 (en) * | 2011-10-13 | 2013-05-02 | Mahmut Bilgic | Liquid pharmaceutical formulations |
| BR102012030828A2 (pt) | 2012-12-03 | 2014-09-16 | Ems Sa | Composição farmacêutica compreendendo desloratadina e prednisolona e seu uso |
| CN104434789B (zh) * | 2014-12-27 | 2017-04-26 | 昆明振华制药厂有限公司 | 一种枸橼酸喷托维林糖浆的制备方法 |
| KR102242382B1 (ko) * | 2020-02-28 | 2021-04-20 | 삼익제약주식회사 | 용해성, 안정성 및 쓴맛이 개선된 로라타딘 함유 시럽 조성물 |
| CN113081958B (zh) * | 2021-05-01 | 2022-05-03 | 安徽新世纪药业有限公司 | 一种地氯雷他定口服溶液及其制备方法 |
| CN114788809B (zh) * | 2022-01-25 | 2023-04-14 | 江苏广承药业有限公司 | 一种氯雷他定液体制剂 |
| CN114767677B (zh) * | 2022-05-06 | 2023-11-07 | 成都倍特药业股份有限公司 | 一种氯雷他定组合物及其制备方法 |
| CN115475141A (zh) * | 2022-10-14 | 2022-12-16 | 漳州片仔癀药业股份有限公司 | 一种地氯雷他定口服溶液及其制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5763449A (en) * | 1996-08-07 | 1998-06-09 | Ascent Pediatrics, Inc. | Pleasant-tasting aqueous liquid composition of a bitter-tasting drug |
| US6132758A (en) * | 1998-06-01 | 2000-10-17 | Schering Corporation | Stabilized antihistamine syrup |
| BR0111018A (pt) * | 2000-05-25 | 2004-02-17 | Schering Corp | Formulações estáveis lìquidas e sólidas |
| US7101572B2 (en) * | 2001-12-07 | 2006-09-05 | Unilab Pharmatech, Ltd. | Taste masked aqueous liquid pharmaceutical composition |
| US20040101563A1 (en) * | 2002-07-18 | 2004-05-27 | Kundu Subhas C. | Storage stable antihistaminic syrup formulations |
| JP3881640B2 (ja) * | 2003-08-08 | 2007-02-14 | 塩野義製薬株式会社 | ロラタジンを含むドライシロップ剤 |
| US20050069590A1 (en) * | 2003-09-30 | 2005-03-31 | Buehler Gail K. | Stable suspensions for medicinal dosages |
| US7758877B2 (en) * | 2004-02-05 | 2010-07-20 | Taro Pharmaceuticals U.S.A., Inc. | Stable loratadine spill resistant formulation |
-
2007
- 2007-06-27 MX MX2009000121A patent/MX2009000121A/es unknown
- 2007-06-27 BR BRPI0713933-0A patent/BRPI0713933A2/pt not_active IP Right Cessation
- 2007-06-27 EP EP07796520A patent/EP2037921A2/en not_active Withdrawn
- 2007-06-27 AR ARP070102860A patent/AR061668A1/es not_active Application Discontinuation
- 2007-06-27 KR KR1020097001410A patent/KR20090024282A/ko not_active Abandoned
- 2007-06-27 CA CA002656087A patent/CA2656087A1/en not_active Abandoned
- 2007-06-27 AU AU2007269835A patent/AU2007269835A1/en not_active Abandoned
- 2007-06-27 WO PCT/US2007/014957 patent/WO2008005267A2/en not_active Ceased
- 2007-06-27 CN CNA2007800314793A patent/CN101505750A/zh active Pending
- 2007-06-27 SG SG2011048220A patent/SG173333A1/en unknown
- 2007-06-27 US US11/769,351 patent/US20080262017A1/en not_active Abandoned
- 2007-06-27 JP JP2009518256A patent/JP2009542665A/ja not_active Withdrawn
- 2007-06-27 PE PE2007000832A patent/PE20080994A1/es not_active Application Discontinuation
- 2007-06-28 CL CL2007001913A patent/CL2007001913A1/es unknown
- 2007-06-28 TW TW096123549A patent/TW200808374A/zh unknown
-
2008
- 2008-12-24 CO CO08136727A patent/CO6230988A2/es not_active Application Discontinuation
-
2009
- 2009-01-08 ZA ZA200900168A patent/ZA200900168B/xx unknown
- 2009-01-28 NO NO20090458A patent/NO20090458L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200900168B (en) | 2010-06-30 |
| US20080262017A1 (en) | 2008-10-23 |
| CO6230988A2 (es) | 2010-12-20 |
| TW200808374A (en) | 2008-02-16 |
| EP2037921A2 (en) | 2009-03-25 |
| NO20090458L (no) | 2009-01-28 |
| AU2007269835A1 (en) | 2008-01-10 |
| BRPI0713933A2 (pt) | 2012-12-18 |
| CL2007001913A1 (es) | 2008-01-11 |
| JP2009542665A (ja) | 2009-12-03 |
| PE20080994A1 (es) | 2008-08-06 |
| WO2008005267A2 (en) | 2008-01-10 |
| WO2008005267A3 (en) | 2008-07-10 |
| MX2009000121A (es) | 2009-01-26 |
| KR20090024282A (ko) | 2009-03-06 |
| SG173333A1 (en) | 2011-08-29 |
| CN101505750A (zh) | 2009-08-12 |
| CA2656087A1 (en) | 2008-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR061668A1 (es) | Jarabes antihistaminicos, estables al almacenamiento, sin azucar | |
| ES2988617T3 (es) | Norketotifeno para el tratamiento de la hipercitocinemia y las infecciones virales | |
| ECSP10010052A (es) | Formulaciones galenicas de alisquireno y valsartan | |
| UY32599A (es) | Formulación oral sólida de abt-263 | |
| DE50212546D1 (de) | Orale darreichungsformen für propiverin oder seinen pharmazeutisch annehmbaren salzen mit verlängerter wirkstofffreisetzung | |
| AR067184A1 (es) | Uso de 6-(3-cloro-2-fluorbencil)-1-[(2s)-1-hidroxi-3-metilbutan-2-il]-7-metoxi-4-oxo-1,4-dihidroquinolina-3-carboxilico. composicion farmaceutica | |
| ATE355065T1 (de) | Therapeutische zusammensetzungen bestehend aus antihypotensiva und antiangiogenika | |
| ECSP088165A (es) | Formulaciones liquidas | |
| AR058133A1 (es) | Metodo de tratamiento y/o prevencion de infecciones en bebes nacidos por cesarea | |
| NO20080220L (no) | Formuleringer med hoy medikament belastning og doseringsformer | |
| AR058679A1 (es) | Preparacion farmaceutica que contiene meloxicam | |
| UA107578C2 (uk) | Комбінована терапія при лікуванні діабету | |
| AR039164A1 (es) | Sales de venlafaxina de baja solubilidad en agua | |
| AR082803A1 (es) | Metodos y formulaciones para el tratamiento de la trombosis con betrixaban y un inhibidor de la glicoproteina p | |
| AR063538A1 (es) | Tratamiento de la enfermedad de parkinson | |
| ATE491452T1 (de) | Pharmazeutische zusammensetzung mit antipsychotischer, antidepressiver oder antiepileptischer wirkung mit verringerter nebenwirkung | |
| AR064543A1 (es) | Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales | |
| PE20020387A1 (es) | Uso de una combinacion de salmeterol y fluticasona | |
| WO2005065648A3 (en) | Novel drug compositions and dosage forms of topiramate | |
| JP2007504194A5 (es) | ||
| CL2008002025A1 (es) | Solución farmacéutica oral que comprende telbivudina, sacarina de sodio, un sabor soluble, ácido benzoico y un buffer citrato, útil para el tratamiento de la hepatitis b en población pediátrica, en personas con dificultades para tragar y en sujetos renalmente perjudicados. | |
| ECSP11010999A (es) | Combinación de dosis fija en la forma de una tableta de dos capas o de una sola capa de alisquireno y amlodipina | |
| GT200600263A (es) | Regimen de dosificacion para prasugrel | |
| AR074246A1 (es) | Derivados de 1-amino-alquilciclohexano para el tratamiento de trastornos del sueno | |
| RU2006131594A (ru) | Гликозидное пролекарство 5-аминосалициловой кислоты |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |